Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sobi

- PMLiVE

Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP

Immune thrombocytopenia is estimated to affect up to 100 people per million

- PMLiVE

Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas

Over 10,000 people are diagnosed with a type of non-Hodgkin lymphoma every year in the UK

- PMLiVE

Scleroderma Research Foundation launches clinical trial platform to advance treatments

The initiative will initially focus on interstitial lung disease secondary to scleroderma but will be expanded to address other manifestations of the disease

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

Sobi to acquire CTI BioPharma for approximately $1.7bn

The deal marks a notable expansion to the Swedish drugmaker's rare haematology pipeline

- PMLiVE

Sanofi and Sobi’s once-weekly haemophilia A treatment approved by FDA

Current factor VIII therapies usually require patients to receive treatment every two days

- PMLiVE

Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia

The IL-Ra1 inhibitor was found to reduce the risk of disease progression by 64%

- PMLiVE

Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A

Phase 3 results showed once-weekly doses provided clinically meaningful bleed protection for patients with haemophilia A

- PMLiVE

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed

- PMLiVE

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

- PMLiVE

Sobi’s Gamifant receives final rejection from CHMP for primary HLH

Committee reiterated previous negative opinion

- PMLiVE

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links